论文部分内容阅读
[目的]探讨早期肠道水疗对重症急性胰腺炎(SAP)患者的临床应用价值。[方法]随机将54例SAP患者分为常规治疗组、肠道水疗组,比较2组患者不同时间的APACHEⅡ评分、CT严重指数(CTSI)、尿乳果糖/甘露醇(L/M)比值、血浆内毒素和二胺氧化酶(DAO)、血清C反应蛋白(CRP)和肿瘤坏死因-α(TNF-α)。[结果]治疗后第7天,肠道水疗组APACHEⅡ评分、尿L/M比值、血浆内毒素和DAO、血清CRP和TNF-α均较常规治疗组显著降低,差异有统计学意义(P<0.05)。入院1周内,2组患者CTSI比较,差异无统计学意义(P>0.05);肠道水疗组患者胰腺感染和MODS发生率明显低于常规治疗组,差异有统计学意义(P<0.05)。[结论]早期应用肠道水疗能明显减轻SAP患者的全身炎症反应,保护肠道黏膜屏障,从而改善其预后。
[Objective] To investigate the clinical value of early intestinal hydrotherapy in patients with severe acute pancreatitis (SAP). [Methods] 54 SAP patients were randomly divided into routine therapy group, gut hydrotherapy group, APACHEⅡscore, CTSI, L / M ratio, Plasma endotoxins and diamine oxidase (DAO), serum C-reactive protein (CRP), and tumor necrosis factor-α (TNF-α). [Result] On the 7th day after treatment, APACHEⅡscore, urine L / M ratio, plasma endotoxin and DAO, serum CRP and TNF-α in intestinal hydrotherapy group were significantly lower than those in the conventional treatment group, with significant difference (P < 0.05). There was no significant difference in CTSI between the two groups (P> 0.05) within 1 week after admission. The incidence of pancreas infection and MODS in patients in gut hydrotherapy group was significantly lower than that in routine treatment group (P <0.05) . [Conclusion] Early application of intestinal hydrotherapy can significantly reduce systemic inflammatory response in SAP patients and protect the intestinal mucosal barrier so as to improve its prognosis.